non fda approved glp 1 takes aim at telehealth companies for promoting unofficial weight loss drug dupes FDA is moving to restrict

GLP-1, GLP-3, semaglutide, tirzepatide, retatrutide

Semaglutide was also associated with reduced craving and drinks per day Data from participants daily logs indicated that those receiving semaglutide had less average alcohol craving each week (small effect size), and on average drank less drinks per drinking day while also having greater reductions in heavy drinking days over time (large effect sizes

The American Heart Association has highlighted growing research into how GLP 1 based medicines may reduce cardiovascular risk in people with obesity and cardiovascular disease

Other SGLT-2 Inhibitors One trial explored the use of the SGLT-2 inhibitors remogliflozin and sergliflozin compared with placebo controls in obese people without co-morbid diabetes over 8 weeks